Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2008 Feb;27(2):249-51.
doi: 10.1007/s10067-007-0704-0. Epub 2007 Jul 28.

A 57-year-old man who developed arthritis during R-CHOP chemotherapy for non-Hodgkin lymphoma

F H Swaneveld  1 , R M van Vugt, J P de Boer, B A C Dijkmans, W F Lems
Affiliations
Case Reports

A 57-year-old man who developed arthritis during R-CHOP chemotherapy for non-Hodgkin lymphoma

F H Swaneveld et al. Clin Rheumatol. 2008 Feb.

Abstract

Rituximab is a chimeric human-mouse anti-CD20 monoclonal antibody, which is used in the treatment of both B-cell lymphomas and rheumatic diseases. We describe a case of a previously healthy 57-year-old man developing arthritis while being treated with rituximab-CHOP chemotherapy (R-CHOP) for a non-Hodgkin lymphoma. The remittant arthritis developed at successively shorter time-intervals after R-CHOP administration and only improved after rituximab was removed from the chemotherapy schedule, suggesting a rituximab-related phenomenon, as extensive diagnostic testing ruled out any other diagnosis.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1007/s00277-003-0747-5', 'is_inner': False, 'url': 'https://doi.org/10.1007/s00277-003-0747-5'}, {'type': 'PubMed', 'value': '14513285', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/14513285/'}]}
    2. Buda-Okreglak EM, Drabick JJ, Delaney NR (2004) Proinflammatory syndrome mimicking acute rheumatoid arthritis in a patient with Waldenstrom’s macroglobulinemia treated with rituximab. Ann Hematol 83:117–119 - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1002/art.21260', 'is_inner': False, 'url': 'https://doi.org/10.1002/art.21260'}, {'type': 'PubMed', 'value': '16142737', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/16142737/'}]}
    2. Pijpe J, van Imhoff GW, Spijkervet FKL, Roodenburg JLN, Wolbink GJ, Mansour K et al (2005) Rituximab treatment in patients with primary Sjögren’s syndrome: an open-label phase ii study. Arthritis Rheum 52(9):2740–2750 - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'PubMed', 'value': '15996570', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/15996570/'}]}
    2. Jardin F, Levesque H, Tilly H (2005) Auto-immune manifestations in Non-Hodgkin’s lymphoma. Rev Med Interne 26(7):557–571 - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'PubMed', 'value': '8235678', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/8235678/'}]}
    2. Kruger R, Oden J, de Leon F, Durr W (1993) Malignant non-Hodgkin’s lymphoma of the joint. Report of two cases, review of the literature and problems of classification. Unfallchirurg 96(10):556–562 - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1056/NEJMoa032534', 'is_inner': False, 'url': 'https://doi.org/10.1056/nejmoa032534'}, {'type': 'PubMed', 'value': '15201414', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/15201414/'}]}
    2. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR et al (2004) Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350(25):2572–2581 - PubMed

Publication types

MeSH terms

Supplementary concepts